No abstract

No abstract

Objectives: To confirm the long-term efficacy and safety of radiofrequency ablation (RFA) for low-risk papillary thyroid microcarcinoma (PTMC). Methods: We retrospectively reviewed data of 102 primary papillary thyroid carcinoma patients (82 women, 20 men; mean age: 43 [19] years) treated with radiofrequency ablation and thyroid-stimulating hormone (TSH) suppression therapy before December 2018. All patients were at high surgical risk or refused surgery. They were followed up at 1, 3, 6, 9, and 12 months and every 6-12 months thereafter using ultrasound and contrast-enhanced ultrasound. The volume and volume reduction ratio was calculated. Recurrence and lymph node or distant metastasis were evaluated. Results: The mean initial tumor diameter was 0.50 (0.29) cm; the mean initial volume was 0.06 (0.09) mL. At 1, 3, 6, 9, 12, 24, 36, 48, and 60 months after RFA, complete resorption rates were 0, 0, 9.8 (10/ 102), 33.3 (34/102), 91.2 (93/102), 96.1 (98/102), 99 (101/102), 100, and 100%, respectively. Two patients had developed ipsilateral neck lymph node metastasis in regions IV and VI at 30-and 18month follow-ups, respectively. After RFA, 3/102 patients (2.9%) developed hoarseness-the main side effect. No life-threatening or delayed complications occurred. The TSH value in the initial period was 0.06 (0.02) mIU/mL; the rate of reaching the TSH target was 85.7%. The TSH value at follow-up was 1.47 (0.91) mIU/mL; the compliance rate was 99.3%. Conclusions: Ultrasound-guided RFA for PTMC is highly effective and safe. RFA can serve as a minimally invasive treatment for PTMC patients who refuse surgery or active surveillance.

With the accelerating process of industrialization and urbanization, as well as the increasing proportion of the elderly in the world's population, we are facing more complex health threats related to bacterial infection. While the vast majority of the bacteria in the body are rendered harmless by the protective effects of the immune system, the continued abuse and misuse of antibiotics has accelerated the spread of antibiotic-resistant bacterial strains and has resulted in substantial new challenges with respect to modern-day antibiotic-based treatments. Therefore, intelligent design of new antibacterial modalities to be used for treating human and livestock diseases is an extremely urgent priority for researchers in the fields of chemistry, chemical engineering, materials and biomedical sciences. Toward this end, the most intriguing of the new developments are metal-organic frameworks (MOFs). MOFs are versatile crystalline porous lattices of organic ligands and metal ion/clusters that formed by self-assembly via coordination bonds. Due to their unique characteristics, including relatively straight forward and simple methods for synthesis, large surface areas, novel and diverse structures, and adjustable porosity, MOFs not only play strong roles with respect to novel methods for gas storage and separation, they may also be utilized in unique applications associated with sensors mechanisms and catalysis. These features contribute to our current understanding of MOFs as promising candidates for the development of pharmaceutical and specifically antibacterial applications. In this review, antibacterial mechanisms, and the development of resistance to current antibiotic strategies are summarized and discussed. The main mechanisms by which bacteria show resistance to antibiotics include altered metabolic pathways, regulation of target sites, and inactivation, modification, and/or reduction in the capacity to accumulate antibacterial drugs. We consider recent progress on the development of MOFs, including the use of specific metal centers and ligands, metal nanoparticles, and drug-encapsulation, all of which have important applications with respect to antibacterial activities, and wound healing. Finally, the challenges and prospects of MOF-based antibacterial materials are discussed, including critical findings, which will help toward the development of the next generation antibacterial MOFs for human use.

The intelligent design of multifunctional nanoplatforms is critical for cancer therapy. Herein, NaGdF 4 :Er,Yb@NaGdF 4 :Nd@Cu(II) boron−imidazolate frameworks (denoted as CSNPs@Cu-BIF) nanoassemblies are designed and fabricated. Upon a single 808 nm laser irradiation, the nanoassemblies not only show the outstanding photothermal conversion capacity (= 41.7%) but also generate cytotoxic reactive oxygen species through an in situ Fenton-like reaction and fluorescence resonance energy transfer. Importantly, the nanoassemblies simultaneously introduce remarkable antitumor efficacy via photothermal/photodynamic/chemodynamic combination therapy both in vitro and in vivo. To improve the therapeutic effect of solid tumor ablation, it is highly desirable to monitor the treatment process in real-time. Multiclinical imaging modalities of ultrasonography are employed to systematically investigate the ablation mechanism of solid tumors in vivo. Furthermore, the significant difference between the eigen temperature of CSNPs@Cu-BIF nanoassemblies obtained by the temperature-sensitive emission bands signal changes and the apparent temperature recorded by the thermal imaging camera is 14.55 K at equilibrium. This current work therefore supplies an alternative strategy in temperature feedback-controlled accurate cancer therapy.